Skip to main content
Louis Matis, MD, Oncology, Southport, CT

LouisMatisMD

Oncology Southport, CT

Senior Adviser, EvolveImmune Therapeutics

Dr. Matis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Matis' full profile

Already have an account?

  • Office

    95 Chester Place
    Southport, CT 06890
    Phone+1 203-521-2003

Education & Training

  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 1975 - 1977
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1975

Certifications & Licensure

  • CT State Medical License
    CT State Medical License 1993 - 2022
  • MD State Medical License
    MD State Medical License 1980 - 1993
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 1991

Publications & Presentations

PubMed

Press Mentions

  • Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International Conference
    Pieris Pharmaceuticals and AstraZeneca Present Single- Ascending Dose Phase 1a Data for Inhaled IL-4Rα Antagonist AZD1402/PRS-060 at the American Thoracic Society (ATS) 2019 International ConferenceMay 22nd, 2019
  • Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
    Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical DevelopmentOctober 12th, 2017
  • Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA Pharmaceutical
    Pieris Signs 1st Partnership for Anemia Drug PRS-080, Granting Exclusive Option in Japan to ASKA PharmaceuticalFebruary 27th, 2017